214 related articles for article (PubMed ID: 10335006)
1. Oxidative stress during acute respiratory exacerbations in cystic fibrosis.
McGrath LT; Mallon P; Dowey L; Silke B; McClean E; McDonnell M; Devine A; Copeland S; Elborn S
Thorax; 1999 Jun; 54(6):518-23. PubMed ID: 10335006
[TBL] [Abstract][Full Text] [Related]
2. Breath isoprene during acute respiratory exacerbation in cystic fibrosis.
McGrath LT; Patrick R; Mallon P; Dowey L; Silke B; Norwood W; Elborn S
Eur Respir J; 2000 Dec; 16(6):1065-9. PubMed ID: 11292107
[TBL] [Abstract][Full Text] [Related]
3. Increased plasma fatty acid concentrations after respiratory exacerbations are associated with elevated oxidative stress in cystic fibrosis patients.
Wood LG; Fitzgerald DA; Gibson PG; Cooper DM; Garg ML
Am J Clin Nutr; 2002 Apr; 75(4):668-75. PubMed ID: 11916752
[TBL] [Abstract][Full Text] [Related]
4. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study.
Wells JM; Farris RF; Gosdin TA; Dransfield MT; Wood ME; Bell SC; Rowe SM
Lancet Respir Med; 2016 Aug; 4(8):636-645. PubMed ID: 27298019
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress.
Brown RK; Wyatt H; Price JF; Kelly FJ
Eur Respir J; 1996 Feb; 9(2):334-9. PubMed ID: 8777973
[TBL] [Abstract][Full Text] [Related]
7. Circulating immunoreactive interleukin-6 in cystic fibrosis.
Nixon LS; Yung B; Bell SC; Elborn JS; Shale DJ
Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1764-9. PubMed ID: 9620903
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Airway and Systemic Malondialdehyde Levels for Assessment of Oxidative Stress in Cystic Fibrosis.
Antus B; Drozdovszky O; Barta I; Kelemen K
Lung; 2015 Aug; 193(4):597-604. PubMed ID: 25951912
[TBL] [Abstract][Full Text] [Related]
9. Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function.
Wood LG; Fitzgerald DA; Lee AK; Garg ML
Am J Clin Nutr; 2003 Jan; 77(1):150-9. PubMed ID: 12499335
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal study of oxidative status in 312 cystic fibrosis patients in stable state and during bronchial exacerbation.
Lagrange-Puget M; Durieu I; Ecochard R; Abbas-Chorfa F; Drai J; Steghens JP; Pacheco Y; Vital-Durand D; Bellon G
Pediatr Pulmonol; 2004 Jul; 38(1):43-9. PubMed ID: 15170872
[TBL] [Abstract][Full Text] [Related]
11. Rhinovirus-associated pulmonary exacerbations show a lack of FEV1 improvement in children with cystic fibrosis.
Cousin M; Molinari N; Foulongne V; Caimmi D; Vachier I; Abely M; Chiron R
Influenza Other Respir Viruses; 2016 Mar; 10(2):109-12. PubMed ID: 26493783
[TBL] [Abstract][Full Text] [Related]
12. Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis.
Reid DW; Misso N; Aggarwal S; Thompson PJ; Walters EH
Respirology; 2007 Jan; 12(1):63-9. PubMed ID: 17207027
[TBL] [Abstract][Full Text] [Related]
13. Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation.
Sagel SD; Thompson V; Chmiel JF; Montgomery GS; Nasr SZ; Perkett E; Saavedra MT; Slovis B; Anthony MM; Emmett P; Heltshe SL
Ann Am Thorac Soc; 2015 May; 12(5):708-17. PubMed ID: 25714657
[TBL] [Abstract][Full Text] [Related]
14. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis.
Conway SP; Pond MN; Watson A; Etherington C; Robey HL; Goldman MH
Thorax; 1997 Nov; 52(11):987-93. PubMed ID: 9487348
[TBL] [Abstract][Full Text] [Related]
15. Plasma biomarkers and cystic fibrosis lung disease.
Cantin AM; Bilodeau G; Larivée P; Richter MV
Clin Invest Med; 2012 Jul; 35(4):E173-81. PubMed ID: 22863555
[TBL] [Abstract][Full Text] [Related]
16. Procalcitonin, erythrocyte sedimentation rate and C-reactive protein in acute pulmonary exacerbations of cystic fibrosis.
Loh G; Ryaboy I; Skabelund A; French A
Clin Respir J; 2018 Apr; 12(4):1545-1549. PubMed ID: 28884501
[TBL] [Abstract][Full Text] [Related]
17. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis.
Renner S; Rath R; Rust P; Lehr S; Frischer T; Elmadfa I; Eichler I
Thorax; 2001 Jan; 56(1):48-52. PubMed ID: 11120904
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory related changes in bone mineral content in adults with cystic fibrosis.
Haworth CS; Selby PL; Webb AK; Martin L; Elborn JS; Sharples LD; Adams JE
Thorax; 2004 Jul; 59(7):613-7. PubMed ID: 15223873
[TBL] [Abstract][Full Text] [Related]
19. Increased sputum amino acid concentrations and auxotrophy of Pseudomonas aeruginosa in severe cystic fibrosis lung disease.
Thomas SR; Ray A; Hodson ME; Pitt TL
Thorax; 2000 Sep; 55(9):795-7. PubMed ID: 10950901
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease.
Thomsen M; Ingebrigtsen TS; Marott JL; Dahl M; Lange P; Vestbo J; Nordestgaard BG
JAMA; 2013 Jun; 309(22):2353-61. PubMed ID: 23757083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
